AVALON PHARMA

Middle East Pharmaceutical Industries Company

4016StocksTadawulHealthcare

Financials

1-5

	CurrentMar 10, 2026	2025Dec 31, 2025	2024Dec 31, 2024	2023Dec 31, 2023	2022Dec 31, 2022
Market & Price
Market Capitalization	2.10B	2.22B	2.44B	—	—
Market Cap Growth	-13.7%	-8.7%	—	—	—
Enterprise Value	2.16B	2.27B	2.50B	—	—
Last Close Price	60.00	62.69	67.43	—	—
Valuation Multiples
Forward PE (Next 12M Est.)	—	22.98	24.86	—	—
PE Ratio	20.09	22.93	30.51	—	—
PS Ratio	4.26	4.83	6.18	—	—
PB Ratio	5.03	5.34	6.62	—	—
P/TBV Ratio	5.32	6.29	7.67	—	—
P/FCF Ratio	39.37	30.16	111.20	—	—
P/OCF Ratio	27.40	25.12	73.65	—	—
EV/Sales Ratio	4.39	4.92	6.33	—	—
EV/EBITDA Ratio	17.17	19.03	25.19	—	—
EV/EBIT Ratio	18.79	21.20	27.95	—	—
EV/FCF Ratio	40.58	30.74	113.93	—	—
Leverage & Capital
Debt / Equity Ratio	0.20	0.15	0.17	0.20	0.30
Debt / EBITDA Ratio	0.66	0.54	0.64	0.73	1.11
Debt / FCF Ratio	1.56	0.87	2.89	0.86	1.44
Net Debt / Equity Ratio	0.16	0.07	0.11	0.15	0.22
Net Debt / EBITDA Ratio	0.51	0.25	0.41	0.55	0.80
Net Debt / FCF Ratio	1.21	0.40	1.85	0.65	1.04
Efficiency & Liquidity
Asset Turnover	0.84	0.82	0.80	0.76	0.70
Inventory Turnover	1.91	1.77	1.68	1.44	1.37
Quick Ratio	2.09	2.24	1.85	1.49	1.36
Current Ratio	2.85	3.13	2.65	2.36	2.22
Returns & Yields
Return on Equity (ROE)	+26.0%	+24.7%	+23.7%	+22.4%	+21.7%
Return on Assets (ROA)	+12.3%	+11.9%	+11.4%	+10.8%	+10.1%
Return on Invested Capital (ROIC)	+23.2%	+23.4%	+21.7%	+20.6%	+18.8%
Return on Capital Employed (ROCE)	+24.2%	+22.9%	+22.7%	+23.4%	+22.3%
Earnings Yield	+5.0%	+4.4%	+3.3%	—	—
FCF Yield	+2.5%	+3.3%	+0.9%	—	—
Dividend Yield	+2.3%	+2.2%	+1.7%	—	—
Payout Ratio	+70.2%	+48.4%	+18.8%	+54.7%	+61.1%
Total Shareholder Return	+2.3%	+2.2%	+1.7%	—	—

1-5

	CurrentMar 10, 2026	2025Dec 31, 2025	2024Dec 31, 2024	2023Dec 31, 2023	2022Dec 31, 2022
Market & Price
Market Capitalization	2.10B	2.22B	2.44B	—	—
Market Cap Growth	-13.7%	-8.7%	—	—	—
Enterprise Value	2.16B	2.27B	2.50B	—	—
Last Close Price	60.00	62.69	67.43	—	—
Valuation Multiples
Forward PE (Next 12M Est.)	—	22.98	24.86	—	—
PE Ratio	20.09	22.93	30.51	—	—
PS Ratio	4.26	4.83	6.18	—	—
PB Ratio	5.03	5.34	6.62	—	—
P/TBV Ratio	5.32	6.29	7.67	—	—
P/FCF Ratio	39.37	30.16	111.20	—	—
P/OCF Ratio	27.40	25.12	73.65	—	—
EV/Sales Ratio	4.39	4.92	6.33	—	—
EV/EBITDA Ratio	17.17	19.03	25.19	—	—
EV/EBIT Ratio	18.79	21.20	27.95	—	—
EV/FCF Ratio	40.58	30.74	113.93	—	—
Leverage & Capital
Debt / Equity Ratio	0.20	0.15	0.17	0.20	0.30
Debt / EBITDA Ratio	0.66	0.54	0.64	0.73	1.11
Debt / FCF Ratio	1.56	0.87	2.89	0.86	1.44
Net Debt / Equity Ratio	0.16	0.07	0.11	0.15	0.22
Net Debt / EBITDA Ratio	0.51	0.25	0.41	0.55	0.80
Net Debt / FCF Ratio	1.21	0.40	1.85	0.65	1.04
Efficiency & Liquidity
Asset Turnover	0.84	0.82	0.80	0.76	0.70
Inventory Turnover	1.91	1.77	1.68	1.44	1.37
Quick Ratio	2.09	2.24	1.85	1.49	1.36
Current Ratio	2.85	3.13	2.65	2.36	2.22
Returns & Yields
Return on Equity (ROE)	+26.0%	+24.7%	+23.7%	+22.4%	+21.7%
Return on Assets (ROA)	+12.3%	+11.9%	+11.4%	+10.8%	+10.1%
Return on Invested Capital (ROIC)	+23.2%	+23.4%	+21.7%	+20.6%	+18.8%
Return on Capital Employed (ROCE)	+24.2%	+22.9%	+22.7%	+23.4%	+22.3%
Earnings Yield	+5.0%	+4.4%	+3.3%	—	—
FCF Yield	+2.5%	+3.3%	+0.9%	—	—
Dividend Yield	+2.3%	+2.2%	+1.7%	—	—
Payout Ratio	+70.2%	+48.4%	+18.8%	+54.7%	+61.1%
Total Shareholder Return	+2.3%	+2.2%	+1.7%	—	—